milrinone has been researched along with Persistent Fetal Circulation Syndrome in 13 studies
Persistent Fetal Circulation Syndrome: A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone was started at an initial dose of 50 mcg/kg, followed by continuous infusion of 0." | 5.38 | Heart failure treated with low-dose milrinone in a full-term newborn. ( Janota, J; Sebková, S; Tomek, V; Zemanová, P, 2012) |
| "It is therefore important to avoid both hypoxemia and hyperoxemia in the management of PPHN." | 2.53 | Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. ( Konduri, GG; Lakshminrusimha, S; Steinhorn, RH, 2016) |
| "Milrinone is a phosphodiesterase III inhibitor which induces pulmonary vasodilatation by its actions through a cyclic adenylate monophosphate mediated signaling pathway." | 2.46 | Milrinone for persistent pulmonary hypertension of the newborn. ( Bassler, D; Kirpalani, H; Kreutzer, K; McNamara, P, 2010) |
| "Milrinone was started at an initial dose of 50 mcg/kg, followed by continuous infusion of 0." | 1.38 | Heart failure treated with low-dose milrinone in a full-term newborn. ( Janota, J; Sebková, S; Tomek, V; Zemanová, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Dillard, J | 1 |
| Pavlek, LR | 1 |
| Korada, S | 1 |
| Chen, B | 1 |
| Imam, SS | 1 |
| El-Farrash, RA | 1 |
| Taha, AS | 1 |
| Saleh, GA | 1 |
| Choobdar, FA | 1 |
| Shahhosseini, P | 1 |
| Vahedi, Z | 1 |
| Khosravi, N | 1 |
| Khalesi, N | 1 |
| Ghassemzadeh, M | 1 |
| Qasim, A | 1 |
| Jain, SK | 1 |
| Mandell, E | 1 |
| Kinsella, JP | 1 |
| Abman, SH | 1 |
| Luecke, C | 1 |
| McPherson, C | 1 |
| Dempsey, E | 1 |
| Rabe, H | 1 |
| Lakshminrusimha, S | 1 |
| Konduri, GG | 1 |
| Steinhorn, RH | 2 |
| Latini, G | 1 |
| Del Vecchio, A | 1 |
| De Felice, C | 1 |
| Verrotti, A | 1 |
| Bossone, E | 1 |
| Bassler, D | 2 |
| Kreutzer, K | 1 |
| McNamara, P | 2 |
| Kirpalani, H | 2 |
| Sebková, S | 1 |
| Tomek, V | 1 |
| Zemanová, P | 1 |
| Janota, J | 1 |
| Choong, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Milrinone Versus Sildenafil in Treatment of PPHN in Neonates[NCT04391478] | Phase 1 | 40 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Effectiveness of Nebulized Magnesium Sulfate Combined With Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn[NCT04898114] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2021-06-02 | Recruiting | ||
| Does Closed-loop Automated Oxygen Control During Mechanical Ventilation Reduce Hypoxic Events? A Randomised Controlled Crossover Study in Ventilated Infants[NCT05017727] | 31 participants (Actual) | Observational | 2021-10-05 | Completed | |||
| Does Closed-loop Automated Oxygen Control During Mechanical Ventilation Reduce the Duration of Supplementary Oxygen Treatment and the Amount of Time Spent in Hyperoxia? A Randomised Trial in Ventilated Infants Born at or Near Term[NCT05657795] | 40 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for milrinone and Persistent Fetal Circulation Syndrome
| Article | Year |
|---|---|
Milrinone Use in Persistent Pulmonary Hypertension of the Newborn.
Topics: Cardiotonic Agents; Humans; Infant, Newborn; Milrinone; Persistent Fetal Circulation Syndrome; Vasoc | 2020 |
Persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Infant; Infant, Newborn; Infant, P | 2021 |
Treatment of Persistent Pulmonary Hypertension of the Newborn: Use of Pulmonary Vasodilators in Term Neonates.
Topics: Bosentan; Humans; Infant, Newborn; Milrinone; Nitric Oxide; Oxygen Inhalation Therapy; Persistent Fe | 2017 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defect | 2019 |
Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates.
Topics: Administration, Inhalation; Animals; Extracorporeal Membrane Oxygenation; Humans; Hyperoxia; Hypoxia | 2016 |
Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates.
Topics: Administration, Inhalation; Animals; Extracorporeal Membrane Oxygenation; Humans; Hyperoxia; Hypoxia | 2016 |
Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates.
Topics: Administration, Inhalation; Animals; Extracorporeal Membrane Oxygenation; Humans; Hyperoxia; Hypoxia | 2016 |
Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates.
Topics: Administration, Inhalation; Animals; Extracorporeal Membrane Oxygenation; Humans; Hyperoxia; Hypoxia | 2016 |
Advances in Neonatal Pulmonary Hypertension.
Topics: Administration, Inhalation; Disease Management; Extracorporeal Membrane Oxygenation; Humans; Hydroco | 2016 |
Persistent pulmonary hypertension of the newborn: therapeutical approach.
Topics: Administration, Inhalation; Humans; Infant, Newborn; Milrinone; Nitric Oxide; Persistent Fetal Circu | 2008 |
Milrinone for persistent pulmonary hypertension of the newborn.
Topics: Humans; Infant, Newborn; Milrinone; Persistent Fetal Circulation Syndrome; Vasodilator Agents | 2010 |
2 trials available for milrinone and Persistent Fetal Circulation Syndrome
| Article | Year |
|---|---|
Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial.
Topics: Humans; Hypertension, Pulmonary; Infant, Newborn; Milrinone; Nitric Oxide; Persistent Fetal Circulat | 2022 |
Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource-limited settings: A randomized clinical trial.
Topics: Administration, Inhalation; Humans; Hypertension, Pulmonary; Infant, Newborn; Milrinone; Nitric Oxid | 2023 |
3 other studies available for milrinone and Persistent Fetal Circulation Syndrome
| Article | Year |
|---|---|
Worsened short-term clinical outcomes in a cohort of patients with iNO-unresponsive PPHN: a case for improving iNO responsiveness.
Topics: Administration, Inhalation; Cohort Studies; Humans; Infant, Newborn; Milrinone; Nitric Oxide; Persis | 2022 |
Heart failure treated with low-dose milrinone in a full-term newborn.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Infant, Newborn; Milrinone; Persistent Fetal Circ | 2012 |
Neonatal persistent pulmonary hypertension treated with milrinone: four case reports.
Topics: Administration, Inhalation; Animals; Female; Gestational Age; Humans; Hypoxia; Infant, Newborn; Infa | 2006 |